FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578448002> ?p ?o ?g. }

• W2578448002 abstract "Despite few studies, a monitoring of a neuromuscular blockade with a train of four (TOF) is recommended in intensive care unit (ICU). Our objective was to compare the results of ulnar and facial TOF measurements with an overall clinical assessment for neuromuscular blockade in ICU patients treated with recommended doses of atracurium or cisatracurium, including patients with acute respiratory disease syndrome (ARDS).We prospectively included in two ICUs 119 patients, 94 with ARDS, who required a neuromuscular blockade for more than 24 h. Three levels of neuromuscular blockade were defined: over-paralyzed (TOF = 0), well-paralyzed (TOF = 1-2), and under-paralyzed (TOF = 3-4). Physicians blinded for TOF counts were asked to classify patients clinically as over-paralyzed, well-paralyzed, or under-paralyzed. Patients were assessed two times daily.For the whole population 996 ulnar and facial TOF measurements and clinical assessments were obtained (846 with cisatracurium and 150 with atracurium). Proportions of patients classified as over-paralyzed, well-paralyzed, and under-paralyzed based on TOF measurements and clinical assessments differed significantly (p < 0.0001). The number of observed agreements between clinical assessments and facial TOF measurements was of 19.08% (κ = 0.06) and of 17.37% with ulnar TOF measurements (κ = 0.04), while it was of 62.75% between ulnar and facial TOF measurements (κ = 0.45). Results were similar for cisatracurium and atracurium. Repeated facial TOF measurements performed on the first 4 days of mechanical ventilation in ARDS patients showed that the proportion of patients TOF = 1-2 was around 8% and did not vary significantly with time (p = 0.9), proportion of patients TOF = 3-4 increased from 24 to 40% (p = 0.01), proportion of patients TOF = 0 decreased from 71 to 53% (p = 0.005) while objectives for protective ventilation were achieved. Proportions of facial and ulnar TOF = 0 were significantly higher among patients with ICU-acquired weakness (ICU-AW) versus those who did not develop ICU-AW (51 vs. 40%, p = 0.03, and 76 vs. 62%, p = 0.006, respectively).The study provides data on clinical and TOF monitoring of neuromuscular blockade, which are widely divergent in ICU patients receiving recommended doses of benzylisoquinoliniums." @default.
• W2578448002 created "2017-01-26" @default.
• W2578448002 creator A5034793955 @default.
• W2578448002 creator A5036047074 @default.
• W2578448002 creator A5036752849 @default.
• W2578448002 creator A5037499142 @default.
• W2578448002 creator A5056072672 @default.
• W2578448002 creator A5061638754 @default.
• W2578448002 creator A5064178366 @default.
• W2578448002 creator A5066487341 @default.
• W2578448002 creator A5067523427 @default.
• W2578448002 creator A5068751805 @default.
• W2578448002 date "2017-01-19" @default.
• W2578448002 modified "2023-10-10" @default.
• W2578448002 title "Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study" @default.
• W2578448002 cites W1898928487 @default.
• W2578448002 cites W1972694996 @default.
• W2578448002 cites W1973798824 @default.
• W2578448002 cites W2011760419 @default.
• W2578448002 cites W2015847732 @default.
• W2578448002 cites W2019049609 @default.
• W2578448002 cites W2038937027 @default.
• W2578448002 cites W2040842974 @default.
• W2578448002 cites W2041572016 @default.
• W2578448002 cites W2044897932 @default.
• W2578448002 cites W2046042870 @default.
• W2578448002 cites W2046612706 @default.
• W2578448002 cites W2053306490 @default.
• W2578448002 cites W2092003768 @default.
• W2578448002 cites W2099066338 @default.
• W2578448002 cites W2099643937 @default.
• W2578448002 cites W2100734600 @default.
• W2578448002 cites W2115186092 @default.
• W2578448002 cites W2128349740 @default.
• W2578448002 cites W2132078502 @default.
• W2578448002 cites W2134089728 @default.
• W2578448002 cites W2144049007 @default.
• W2578448002 cites W2146346947 @default.
• W2578448002 cites W2150866864 @default.
• W2578448002 cites W2152146231 @default.
• W2578448002 cites W2155900726 @default.
• W2578448002 cites W2169283873 @default.
• W2578448002 cites W2208931577 @default.
• W2578448002 cites W2311641740 @default.
• W2578448002 cites W2326892364 @default.
• W2578448002 cites W2331048724 @default.
• W2578448002 cites W2332748617 @default.
• W2578448002 cites W2335341134 @default.
• W2578448002 cites W2597070792 @default.
• W2578448002 cites W3144999215 @default.
• W2578448002 cites W4245525675 @default.
• W2578448002 cites W4247943214 @default.
• W2578448002 cites W69636228 @default.
• W2578448002 doi "https://doi.org/10.1186/s13613-017-0234-0" @default.
• W2578448002 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5247382" @default.
• W2578448002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28102521" @default.
• W2578448002 hasPublicationYear "2017" @default.
• W2578448002 type Work @default.
• W2578448002 sameAs 2578448002 @default.
• W2578448002 citedByCount "32" @default.
• W2578448002 countsByYear W25784480022017 @default.
• W2578448002 countsByYear W25784480022018 @default.
• W2578448002 countsByYear W25784480022019 @default.
• W2578448002 countsByYear W25784480022020 @default.
• W2578448002 countsByYear W25784480022021 @default.
• W2578448002 countsByYear W25784480022022 @default.
• W2578448002 countsByYear W25784480022023 @default.
• W2578448002 crossrefType "journal-article" @default.
• W2578448002 hasAuthorship W2578448002A5034793955 @default.
• W2578448002 hasAuthorship W2578448002A5036047074 @default.
• W2578448002 hasAuthorship W2578448002A5036752849 @default.
• W2578448002 hasAuthorship W2578448002A5037499142 @default.
• W2578448002 hasAuthorship W2578448002A5056072672 @default.
• W2578448002 hasAuthorship W2578448002A5061638754 @default.
• W2578448002 hasAuthorship W2578448002A5064178366 @default.
• W2578448002 hasAuthorship W2578448002A5066487341 @default.
• W2578448002 hasAuthorship W2578448002A5067523427 @default.
• W2578448002 hasAuthorship W2578448002A5068751805 @default.
• W2578448002 hasBestOaLocation W25784480021 @default.
• W2578448002 hasConcept C126322002 @default.
• W2578448002 hasConcept C206044474 @default.
• W2578448002 hasConcept C2776348555 @default.
• W2578448002 hasConcept C2776376669 @default.
• W2578448002 hasConcept C2777080012 @default.
• W2578448002 hasConcept C2777714996 @default.
• W2578448002 hasConcept C2778717843 @default.
• W2578448002 hasConcept C2779526319 @default.
• W2578448002 hasConcept C2909465803 @default.
• W2578448002 hasConcept C3020341438 @default.
• W2578448002 hasConcept C42219234 @default.
• W2578448002 hasConcept C71924100 @default.
• W2578448002 hasConceptScore W2578448002C126322002 @default.
• W2578448002 hasConceptScore W2578448002C206044474 @default.
• W2578448002 hasConceptScore W2578448002C2776348555 @default.
• W2578448002 hasConceptScore W2578448002C2776376669 @default.
• W2578448002 hasConceptScore W2578448002C2777080012 @default.
• W2578448002 hasConceptScore W2578448002C2777714996 @default.
• W2578448002 hasConceptScore W2578448002C2778717843 @default.
• W2578448002 hasConceptScore W2578448002C2779526319 @default.
• W2578448002 hasConceptScore W2578448002C2909465803 @default.

• next